Regeneron (REGN)
675.19
0.00 (0.00%)
Upcoming Events
Latest Headlines
Regeneron Pharma (REGN) PT Raised to $1,000 at Guggenheim
July 21, 2026 6:45 AM - StreetInsider
Regeneron Pharma (REGN) Reiterated at Overweight by Cantor Fitzgerald
July 13, 2026 7:41 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $854 at Piper Sandler
July 9, 2026 7:11 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $730 at Morgan Stanley
July 8, 2026 8:08 AM - StreetInsider
Form 4 REGENERON PHARMACEUTICAL For: Jul 02 Filed by: RYAN ARTHUR F
July 7, 2026 4:05 PM - SEC Filing
Regeneron Pharma (REGN) PT Lowered to $696 at RBC Capital
July 7, 2026 7:55 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $769 at Truist Securities
July 7, 2026 7:09 AM - StreetInsider
Form 8-K REGENERON PHARMACEUTICAL For: Jul 06
July 6, 2026 7:01 AM - SEC Filing
Regeneron Pharma (REGN) PT Lowered to $750 at Cantor Fitzgerald on Negative Eylea Optics
July 6, 2026 6:46 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $800 at HSBC
July 6, 2026 1:35 AM - StreetInsider
Form 144 REGENERON PHARMACEUTICAL Filed by: RYAN ARTHUR F
July 2, 2026 5:46 PM - SEC Filing
FDA selects 7 companies for domestic drug manufacturing pilot
June 29, 2026 4:20 PM - StreetInsider
From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak
June 26, 2026 7:02 AM - StreetInsider
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
June 25, 2026 4:05 PM - StreetInsider
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
June 22, 2026 7:00 AM - StreetInsider
Form 8-K REGENERON PHARMACEUTICAL For: Jun 12
June 17, 2026 4:06 PM - SEC Filing
Regeneron to present clinical data at medical conferences
June 4, 2026 7:00 AM - StreetInsider
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
June 4, 2026 7:00 AM - StreetInsider
WHO recommends Regeneron antibody for Bundibugyo Ebola outbreak
May 28, 2026 4:01 PM - StreetInsider
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
May 28, 2026 4:00 PM - StreetInsider
Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG
May 27, 2026 8:37 AM - StreetInsider
Important Notice to Long-Term Shareholders of Molina Healthcare, Inc. (NYSE: MOH); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASD
May 26, 2026 8:18 AM - StreetInsider
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)
May 25, 2026 11:33 AM - StreetInsider
Regeneron's Otarmeni gains EMA review for genetic hearing loss
May 22, 2026 7:01 AM - StreetInsider
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
May 22, 2026 7:00 AM - StreetInsider
Regeneron reports positive linvoseltamab results in rare blood disorder
May 21, 2026 5:02 PM - StreetInsider
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
May 21, 2026 5:01 PM - Globe NewsWire
Regeneron Pharma (REGN) PT Lowered to $875 at Canaccord
May 19, 2026 6:38 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $860 at Wolfe Research
May 18, 2026 3:46 PM - StreetInsider
Regeneron (REGN) call put ratio 1 call to 1.2 puts as share price down 9.9%
May 18, 2026 3:35 PM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $785 at Cantor Fitzgerald on Disappointing Trial Results
May 18, 2026 8:59 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $850 at JPMorgan
May 18, 2026 8:07 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $855 at Piper Sandler Following Setback
May 18, 2026 7:45 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $730 at BMO Capital Following LAG-3 Miss
May 18, 2026 7:40 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $861 at Bernstein SocGen Group
May 18, 2026 7:24 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $700 at Wells Fargo
May 18, 2026 7:02 AM - StreetInsider
Regeneron partners with Parabilis for $125M antibody conjugate deal
May 18, 2026 7:01 AM - StreetInsider
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
May 18, 2026 7:00 AM - Globe NewsWire
Regeneron shares fall 12% on disappointing melanoma trial data
May 18, 2026 6:18 AM - StreetInsider
Leerink Partners Downgrades Regeneron Pharma (REGN) to Market Perform, 'on LAG-3 Failure and Eylea Erosion Risk'
May 18, 2026 6:05 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $778 at Truist Securities
May 18, 2026 5:21 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $707 at RBC Capital
May 18, 2026 5:14 AM - StreetInsider
Citi Downgrades Regeneron Pharma (REGN) to Neutral
May 18, 2026 3:18 AM - StreetInsider
BofA Securities Reiterates Buy Rating on Regeneron Pharma (REGN)
May 18, 2026 1:01 AM - StreetInsider
Regeneron melanoma drug trial fails to meet primary endpoint
May 15, 2026 8:19 PM - StreetInsider
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
May 15, 2026 8:19 PM - Globe NewsWire
UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
May 15, 2026 5:56 PM - Globe NewsWire
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
May 15, 2026 4:27 PM - Globe NewsWire
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
May 15, 2026 2:09 PM - Globe NewsWire
Biologics Market Momentum Accelerates Across Healthcare, AI, And Global Medical Tourism
May 15, 2026 10:15 AM - StreetInsider
Form 13F-HR REGENERON PHARMACEUTICAL For: Mar 31
May 8, 2026 4:11 PM - SEC Filing
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
May 8, 2026 7:00 AM - Globe NewsWire
Biotech’s Next Wave May Already be in Motion
May 7, 2026 8:45 AM - Globe NewsWire
Dupixent shows improved esophageal function in phase 4 trial for EoE
May 5, 2026 7:01 AM - StreetInsider
Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
May 5, 2026 7:00 AM - Globe NewsWire
Form 4 REGENERON PHARMACEUTICAL For: May 01 Filed by: RYAN ARTHUR F
May 4, 2026 4:15 PM - SEC Filing
Regeneron Pharma (REGN) PT Raised to $995 at Guggenheim
April 30, 2026 2:49 PM - StreetInsider
Form SCHEDULE 13G REGENERON PHARMACEUTICAL Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 1:03 PM - SEC Filing
Regeneron Pharma (REGN) PT Lowered to $762 at RBC Capital
April 30, 2026 8:43 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $800 at Wells Fargo
April 30, 2026 8:35 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $788 at Morgan Stanley
April 30, 2026 7:58 AM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $916 at Bernstein SocGen Group
April 30, 2026 7:34 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $917 at Barclays
April 30, 2026 6:02 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $769 at Truist Securities
April 29, 2026 4:21 PM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $902 at Raymond James
April 29, 2026 12:35 PM - StreetInsider
Regeneron beats first quarter estimates on Dupixent strength
April 29, 2026 6:55 AM - StreetInsider
Form 10-Q REGENERON PHARMACEUTICAL For: Mar 31
April 29, 2026 6:55 AM - SEC Filing
Form 8-K REGENERON PHARMACEUTICAL For: Apr 29
April 29, 2026 6:50 AM - SEC Filing
Regeneron (REGN) Tops Q1 EPS by 50c, Beats on Revenue
April 29, 2026 6:31 AM - StreetInsider
Regeneron Reports First Quarter 2026 Financial and Operating Results
April 29, 2026 6:30 AM - Globe NewsWire
U.S. Biotech stocks: Q1 earnings previews
April 26, 2026 8:00 PM - StreetInsider
Form ARS REGENERON PHARMACEUTICAL For: Dec 31
April 24, 2026 4:14 PM - SEC Filing
Form DEF 14A REGENERON PHARMACEUTICAL For: Jun 12
April 24, 2026 4:06 PM - SEC Filing
Form DEFA14A REGENERON PHARMACEUTICAL
April 24, 2026 4:05 PM - SEC Filing
Piper Sandler on Regeneron Pharma (REGN): 'Channel Checks Point to Branded Anti-VEGF Expansion'
April 24, 2026 9:00 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $913 at Bernstein SocGen
April 24, 2026 8:34 AM - StreetInsider
Regeneron agrees to lower drug prices, offer gene therapy for free
April 23, 2026 3:46 PM - StreetInsider
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
April 23, 2026 3:46 PM - Globe NewsWire
Regeneron to offer prescriptions at most favored nation prices, Trump says
April 23, 2026 3:25 PM - StreetInsider
Regeneron wins FDA approval for gene therapy treating rare hearing loss
April 23, 2026 12:53 PM - StreetInsider
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
April 23, 2026 12:40 PM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $960 at TD Cowen
April 23, 2026 6:34 AM - StreetInsider
Full Article List
